[go: up one dir, main page]

PE20140252A1 - ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf - Google Patents

((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf

Info

Publication number
PE20140252A1
PE20140252A1 PE2013000789A PE2013000789A PE20140252A1 PE 20140252 A1 PE20140252 A1 PE 20140252A1 PE 2013000789 A PE2013000789 A PE 2013000789A PE 2013000789 A PE2013000789 A PE 2013000789A PE 20140252 A1 PE20140252 A1 PE 20140252A1
Authority
PE
Peru
Prior art keywords
indazol
vinyl
dichloropidin
fgrf
etoxy
Prior art date
Application number
PE2013000789A
Other languages
English (en)
Inventor
Benjamin Alan Diseroad
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44999860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140252(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20140252A1 publication Critical patent/PE20140252A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA AL COMPUESTO MONOHIDRATO DE ((R)-(E)-2-(4-(2-(5-(1-(3,5-DICLOROPIRIDIN-4-IL)ETOXI)-1H-INDAZOL-3-IL)VINIL)-1H-PIRAZOL-1-IL)ETANOL CRISTALINO QUE PRESENTA UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X QUE COMPRENDE PICOS A 14,65, 3,54, 12,51 Y 19,16 (2 THETA +/- 0,1�). TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DEL CANCER
PE2013000789A 2010-10-05 2011-09-29 ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf PE20140252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38991110P 2010-10-05 2010-10-05

Publications (1)

Publication Number Publication Date
PE20140252A1 true PE20140252A1 (es) 2014-03-12

Family

ID=44999860

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000789A PE20140252A1 (es) 2010-10-05 2011-09-29 ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf

Country Status (35)

Country Link
US (1) US8530665B2 (es)
EP (1) EP2625175B1 (es)
JP (1) JP5940547B2 (es)
KR (1) KR101527661B1 (es)
CN (1) CN103153983B (es)
AR (1) AR083091A1 (es)
AU (1) AU2011312485B2 (es)
BR (1) BR112013006336A2 (es)
CA (1) CA2813329C (es)
CL (1) CL2013000884A1 (es)
CO (1) CO6710911A2 (es)
DK (1) DK2625175T3 (es)
DO (1) DOP2013000072A (es)
EA (1) EA021817B1 (es)
EC (1) ECSP13012539A (es)
ES (1) ES2558777T3 (es)
HR (1) HRP20151299T1 (es)
HU (1) HUE026379T2 (es)
IL (1) IL224850A (es)
JO (1) JO3062B1 (es)
MA (1) MA34552B1 (es)
ME (1) ME02307B (es)
MX (1) MX2013003907A (es)
NZ (1) NZ608482A (es)
PE (1) PE20140252A1 (es)
PH (1) PH12013500649A1 (es)
PL (1) PL2625175T3 (es)
PT (1) PT2625175E (es)
RS (1) RS54457B1 (es)
SG (1) SG188286A1 (es)
SI (1) SI2625175T1 (es)
TW (1) TWI418554B (es)
UA (1) UA111725C2 (es)
WO (1) WO2012047699A1 (es)
ZA (1) ZA201301560B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
NZ702747A (en) 2012-06-13 2017-03-31 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
CN103819396B (zh) * 2014-02-26 2016-06-15 四川大学 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3788046B1 (en) 2018-05-04 2025-12-10 Incyte Corporation Salts of an fgfr inhibitor
EP4309737A3 (en) 2018-05-04 2024-03-27 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111705099B (zh) * 2020-07-01 2022-03-08 天津药明康德新药开发有限公司 一种(s)-1-(3,5-二氯吡啶-4-取代)乙醇的制备方法
US20240182487A1 (en) * 2020-12-17 2024-06-06 Blossomhill Therapeutics, Inc. Macrocycles and their use
CN116635076A (zh) * 2020-12-17 2023-08-22 荣山医药股份有限公司 大环化合物及其用途
WO2022147246A1 (en) * 2020-12-30 2022-07-07 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
HU230787B1 (en) 2000-09-11 2018-05-02 Novartis Vaccines & Diagnostics Inc Quinolinone derivatives as tyrosine kinase inhibitors
IL164209A0 (en) 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
WO2005090331A1 (en) * 2004-03-17 2005-09-29 Pfizer Inc. Polymorphic and amorphous forms of 2,5-dimethyl-2h-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indasol-6-ylamino]-phenyl}-amide
JP4746299B2 (ja) * 2004-07-16 2011-08-10 ジュズ インターナショナル ピーティーイー エルティーディー 金属酸化物粉末の製造方法
JP2006163651A (ja) 2004-12-03 2006-06-22 Sony Computer Entertainment Inc 表示装置、表示装置の制御方法、プログラム及びフォントデータ
US20060160863A1 (en) * 2005-01-05 2006-07-20 Agouron Pharmaceuticals, Inc. Polymorphic and amorphous forms of 2-{3-[(E)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-N-(4-hydroxy-but-2-ynyl)benzamide
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
CN103626739B (zh) * 2007-04-05 2015-12-30 辉瑞产品公司 适用于治疗哺乳动物异常细胞生长的6-[2-(甲基-氨甲酰基)苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型
AR078411A1 (es) * 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende

Also Published As

Publication number Publication date
ECSP13012539A (es) 2013-06-28
EP2625175B1 (en) 2015-11-18
PT2625175E (pt) 2016-01-22
DK2625175T3 (en) 2016-02-01
HK1184147A1 (zh) 2014-01-17
KR20130052680A (ko) 2013-05-22
AU2011312485A1 (en) 2013-03-07
US20120083511A1 (en) 2012-04-05
SG188286A1 (en) 2013-04-30
US8530665B2 (en) 2013-09-10
CA2813329A1 (en) 2012-04-12
UA111725C2 (uk) 2016-06-10
TWI418554B (zh) 2013-12-11
ZA201301560B (en) 2014-08-27
RS54457B1 (sr) 2016-06-30
HRP20151299T1 (hr) 2016-01-01
MX2013003907A (es) 2013-06-03
BR112013006336A2 (pt) 2019-09-24
CN103153983B (zh) 2014-11-05
AU2011312485B2 (en) 2014-09-04
KR101527661B1 (ko) 2015-06-09
EA201390275A1 (ru) 2013-07-30
NZ608482A (en) 2014-03-28
JP5940547B2 (ja) 2016-06-29
WO2012047699A1 (en) 2012-04-12
PL2625175T3 (pl) 2016-04-29
ME02307B (me) 2016-06-20
MA34552B1 (fr) 2013-09-02
IL224850A (en) 2016-09-29
AR083091A1 (es) 2013-01-30
CO6710911A2 (es) 2013-07-15
EP2625175A1 (en) 2013-08-14
JP2013538875A (ja) 2013-10-17
HUE026379T2 (en) 2016-06-28
JO3062B1 (ar) 2017-03-15
SI2625175T1 (sl) 2016-01-29
EA021817B1 (ru) 2015-09-30
DOP2013000072A (es) 2013-08-15
CL2013000884A1 (es) 2013-10-18
CN103153983A (zh) 2013-06-12
TW201249826A (en) 2012-12-16
CA2813329C (en) 2015-05-26
PH12013500649A1 (en) 2013-05-06
ES2558777T3 (es) 2016-02-08

Similar Documents

Publication Publication Date Title
PE20140252A1 (es) ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf
PE20120812A1 (es) Compuestos vinil indazolilo
NZ621221A (en) Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
CO7160104A2 (es) Inhibidores de virus de hepatitis c
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
PE20120250A1 (es) Composicion farmaceutica que comprende derivados de glucopiranosil difenilmetano, forma farmaceutica de la misma, procedimiento para su preparacion
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
CL2008003041A1 (es) Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
PE20140065A1 (es) Sal(es) de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico y procesos para su elaboracion
MX385616B (es) Inhibidores de cdk
IN2015DN00185A (es)
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
BR112013029999A2 (pt) derivados de tiazol
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
ECSP11011151A (es) Compuestos purina
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
MX2011012199A (es) Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.

Legal Events

Date Code Title Description
FC Refusal